Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-08-2018 | Short Communication

Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease

Authors: Panagiotis Alexopoulos, Lena-Sophie Gleixner, Lukas Werle, Felix Buhl, Nathalie Thierjung, Evangelia Giourou, Simone M. Kagerbauer, Philippos Gourzis, Hubert Kübler, Timo Grimmer, Igor Yakushev, Jan Martin, Alexander Kurz, Robert Perneczky

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 5/2018

Abstract

The established biomarkers of Alzheimer’s disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein β (sAPPβ), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPPβ in plasma as an AD biomarker candidate.

Available only for authorised users

Dubois B, Feldman HH, Jacova C et al (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13(6):614–629. doi:10.1016/S1474-4422(14)70090-0 CrossRefPubMed

McKhann GM (2011) Changing concepts of Alzheimer disease. JAMA 305(23):2458–2459. doi:10.1001/jama.2011.810 CrossRefPubMed

Alexopoulos P, Kurz A (2015) The new conceptualization of Alzheimer’s disease under the microscope of influential definitions of disease. Psychopathology 48(6):359–367. doi:10.1159/000441327 CrossRefPubMed

Martins-de-Souza D (2010) Is the word ‘biomarker’ being properly used by proteomics research in neuroscience? Eur Arch Psychiatry Clin Neurosci 260(7):561–562. doi:10.1007/s00406-010-0105-2 CrossRefPubMedPubMedCentral

Herukka S-K, Simonsen AH, Andreasen N et al (2017) Recommendations for cerebrospinal fluid Alzheimer’s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer’s Dement 13(3):285–295. doi:10.1016/j.jalz.2016.09.009 CrossRef

Simonsen AH, Herukka S-K, Andreasen N et al (2017) Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer’s Dement 13(3):274–284. doi:10.1016/j.jalz.2016.09.008 CrossRef

Plassman BL, Khachaturian AS, Townsend JJ et al (2006) Comparison of clinical and neuropathologic diagnoses of Alzheimer’s disease in 3 epidemiologic samples. Alzheimer’s Dement 2(1):2–11. doi:10.1016/j.jalz.2005.11.001 CrossRef

Weiner MW, Veitch DP, Aisen PS et al (2017) Recent publications from the Alzheimer’s disease neuroimaging initiative: reviewing progress toward improved AD clinical trials. Alzheimer’s Dement. doi:10.1016/j.jalz.2016.11.007 CrossRef

Skillbäck T, Farahmand BY, Rosén C et al (2015) Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia. Brain 138(9):2716–2731. doi:10.1093/brain/awv181 CrossRefPubMed

10.

Alexopoulos P, Kriett L, Haller B et al (2014) Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer’s disease. Alzheimer’s Dement 10(6):684–689. doi:10.1016/j.jalz.2014.03.006 CrossRef

11.

Alexopoulos P, Roesler J, Thierjung N et al (2015) Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. doi:10.1007/s00406-015-0628-7 PubMedCrossRef

12.

McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7(3):263–269. doi:10.1016/j.jalz.2011.03.005 CrossRef

13.

Albert MS, DeKosky ST, Dickson D et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement 7(3):270–279. doi:10.1016/j.jalz.2011.03.008 CrossRef

14.

Petersen RC, Aisen P, Boeve BF et al (2013) Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol 74(2):199–208. doi:10.1002/ana.23931 PubMedPubMedCentralCrossRef

15.

Perneczky R, Alexopoulos P, Kurz A (2014) Soluble amyloid precursor proteins and secretases as Alzheimer’s disease biomarkers. Trends Mol Med 20(1):8–15CrossRefPubMed

16.

Smailagic N, Vacante M, Hyde C (2015) 18F-FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev 1:CD010632. doi:10.1002/14651858.CD010632.pub2 PubMedCrossRef

17.

Perneczky R, Guo LH, Kagerbauer SM et al (2013) Soluble amyloid precursor protein beta as blood-based biomarker of Alzheimer’s disease. Transl Psychiatry 3:e227. doi:10.1038/tp.2013.11 CrossRefPubMedPubMedCentral

18.

Wu G, Sankaranarayanan S, Hsieh SH-K et al (2011) Decrease in brain soluble amyloid precursor protein beta (sAPPbeta) in Alzheimer’s disease cortex. J Neurosci Res 89(6):822–832. doi:10.1002/jnr.22618 CrossRefPubMed

19.

Alexopoulos P, Grimmer T, Perneczky R et al (2006) Progression to dementia in clinical subtypes of mild cognitive impairment. Dement Geriatr Cogn Disord 22(1):27–34. doi:10.1159/000093101 CrossRefPubMed

20.

Perneczky R, Drzezga A, Boecker H et al (2010) Metabolic alterations associated with impaired clock drawing in Lewy body dementia. Psychiatry Res 181(2):85–89. doi:10.1016/j.pscychresns.2009.08.001 CrossRefPubMed

21.

Alexopoulos P, Guo L-H, Jiang M et al (2013) Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer’s disease cerebral metabolic signature. J Alzheimers Dis 36(2):401–408. doi:10.3233/JAD-122329 CrossRefPubMed

22.

Jagust WJ, Landau SM, Shaw LM et al (2009) Relationships between biomarkers in aging and dementia. Neurology 73(15):1193–1199. doi:10.1212/WNL.0b013e3181bc010c CrossRefPubMedPubMedCentral

23.

Hulstaert F, Blennow K, Ivanoiu A et al (1999) Improved discrimination of AD patients using beta-amyloid (1–42) and tau levels in CSF. Neurology 52(8):1555–1562CrossRefPubMed

24.

Wenham PR, Price WH, Blandell G (1991) Apolipoprotein E genotyping by one-stage PCR. Lancet (London, England) 337(8750):1158–1159CrossRef

25.

Olsson B, Lautner R, Andreasson U et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease. A systematic review and meta-analysis. Lancet Neurol 15(7):673–684. doi:10.1016/S1474-4422(16)00070-3 CrossRefPubMed

26.

Zhang S, Smailagic N, Hyde C et al. (2014) 11C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev (7):CD010386. doi:10.1002/14651858.CD010386.pub2

27.

Wu G, Sankaranarayanan S, Tugusheva K et al (2008) Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer’s subjects. Clin Biochem 41(12):986–996. doi:10.1016/j.clinbiochem.2008.04.022 CrossRefPubMed

28.

Kitazume S, Yoshihisa A, Yamaki T et al (2012) Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: a novel biomarker for acute coronary syndrome. J Biol Chem 287(48):40817–40825. doi:10.1074/jbc.M112.398578 CrossRefPubMedPubMedCentral

29.

Marksteiner J, Humpel C (2013) Platelet-derived secreted amyloid-precursor protein-beta as a marker for diagnosing Alzheimer’s disease. Curr Neurovasc Res 10(4):297–303CrossRefPubMedPubMedCentral

30.

Delvaux E, Bentley K, Stubbs V et al (2013) Differential processing of amyloid precursor protein in brain and in peripheral blood leukocytes. Neurobiol Aging 34(6):1680–1686. doi:10.1016/j.neurobiolaging.2012.12.004 CrossRefPubMedPubMedCentral

31.

Xiang Y, Bu X-L, Liu Y-H et al (2015) Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease. Acta Neuropathol 130(4):487–499. doi:10.1007/s00401-015-1477-1 CrossRefPubMedPubMedCentral

32.

Roher AE, Esh CL, Kokjohn TA et al (2009) Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer’s disease. Alzheimer’s Dement 5(1):18–29. doi:10.1016/j.jalz.2008.10.004 CrossRef

33.

Vignini A, Sartini D, Morganti S et al (2011) Platelet amyloid precursor protein isoform expression in Alzheimer’s disease: evidence for peripheral marker. Int J Immunopathol Pharmacol 24(2):529–534CrossRefPubMed

34.

Jiang S, Zhang M, Ren D et al (2003) Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer’s disease. American journal of medical genetics. Part B Psychiatr Genet 118B(1):99–102. doi:10.1002/ajmg.b.10067 CrossRef

35.

Chasseigneaux S, Allinquant B (2012) Functions of Abeta, sAPPalpha and sAPPbeta. Similarities and differences. J Neurochem 120(1):99–108. doi:10.1111/j.1471-4159.2011.07584.x CrossRefPubMed

36.

Kitazume S, Yoshihisa A, Yamaki T et al (2012) Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: a novel biomarker for acute coronary syndrome. J Bio Chem 287(48):40817–40825. doi:10.1074/jbc.M112.398578 CrossRef

37.

Title: Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease
Authors: Panagiotis Alexopoulos
Lena-Sophie Gleixner
Lukas Werle
Felix Buhl
Nathalie Thierjung
Evangelia Giourou
Simone M. Kagerbauer
Philippos Gourzis
Hubert Kübler
Timo Grimmer
Igor Yakushev
Jan Martin
Alexander Kurz
Robert Perneczky
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 5/2018
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-017-0815-9

ACC 2024 Congress

Springer Medicine

Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

Articulation and testing of a personality-centred model of psychopathology: evidence from a longitudinal community study over 30 years

The association of psychopathology with concurrent level of functioning and subjective well-being in persons with schizophrenia spectrum disorders

Biomarkers for Alzheimer’s disease: from pathogenesis to drug development

Dysfunction of the blood-cerebrospinal fluid-barrier and N-methyl-d-aspartate glutamate receptor antibodies in dementias

Planning functioning and impulsiveness in obsessive–compulsive disorder

Effects of neonatal excitotoxic lesions in ventral thalamus on social interaction in the rat